A phase 1 trial evaluated the safety, feasibility, and activity of CAR-T cell therapy in HER2-overexpressing advanced BTCs (and also in pancreatic cancers) [71]. The gene discussed is ERBB2; the disease is familial pancreatic carcinoma.